X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2634) 2634
Book Review (345) 345
Publication (216) 216
Newsletter (6) 6
Conference Proceeding (4) 4
Book Chapter (3) 3
Magazine Article (2) 2
Transcript (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2467) 2467
index medicus (2412) 2412
female (1702) 1702
male (1698) 1698
middle aged (1494) 1494
oncology (1406) 1406
adult (1405) 1405
dacarbazine - administration & dosage (1214) 1214
aged (1205) 1205
dacarbazine - analogs & derivatives (1182) 1182
dacarbazine - adverse effects (1157) 1157
antineoplastic combined chemotherapy protocols - therapeutic use (976) 976
chemotherapy (922) 922
dacarbazine - therapeutic use (892) 892
temozolomide (785) 785
antineoplastic combined chemotherapy protocols - adverse effects (774) 774
treatment outcome (692) 692
cancer (618) 618
melanoma - drug therapy (604) 604
brain neoplasms - drug therapy (547) 547
dacarbazine (527) 527
antineoplastic agents, alkylating - therapeutic use (483) 483
radiotherapy (470) 470
antineoplastic agents, alkylating - adverse effects (454) 454
adolescent (449) 449
disease-free survival (446) 446
melanoma (426) 426
combined modality therapy (425) 425
doxorubicin - administration & dosage (396) 396
hodgkin disease - drug therapy (368) 368
glioblastoma - drug therapy (354) 354
glioblastoma (353) 353
care and treatment (350) 350
antineoplastic combined chemotherapy protocols - administration & dosage (314) 314
medicine & public health (312) 312
bleomycin - administration & dosage (302) 302
survival (301) 301
doxorubicin - adverse effects (300) 300
aged, 80 and over (297) 297
drug administration schedule (293) 293
prognosis (293) 293
clinical neurology (292) 292
vincristine - administration & dosage (290) 290
retrospective studies (287) 287
young adult (286) 286
skin neoplasms - drug therapy (282) 282
survival analysis (273) 273
therapy (264) 264
neoplasm staging (261) 261
vinblastine - administration & dosage (258) 258
antineoplastic agents, alkylating - administration & dosage (256) 256
trial (252) 252
survival rate (247) 247
abridged index medicus (242) 242
bleomycin - adverse effects (242) 242
metastatic melanoma (236) 236
gliomas (231) 231
glioma - drug therapy (229) 229
glioblastoma multiforme (226) 226
follow-up studies (219) 219
antineoplastic agents - therapeutic use (217) 217
melanoma - pathology (216) 216
brain neoplasms - pathology (214) 214
malignant glioma (212) 212
brain neoplasms - radiotherapy (209) 209
melanoma - secondary (204) 204
tumors (203) 203
antineoplastic agents - adverse effects (202) 202
vinblastine - adverse effects (197) 197
brain neoplasms - mortality (195) 195
hematology (193) 193
brain neoplasms - therapy (187) 187
phase-ii (186) 186
clinical trials (184) 184
toxicity (184) 184
vincristine - adverse effects (184) 184
kaplan-meier estimate (181) 181
analysis (178) 178
drug therapy (178) 178
vinblastine (176) 176
adjuvant temozolomide (173) 173
pharmacology & pharmacy (173) 173
procarbazine - administration & dosage (173) 173
skin neoplasms - pathology (172) 172
antineoplastic agents (171) 171
child (170) 170
animals (169) 169
disease progression (169) 169
neoplasm metastasis (169) 169
metastasis (168) 168
radiation-therapy (168) 168
glioblastoma - radiotherapy (167) 167
malignant-melanoma (166) 166
immunotherapy (165) 165
research (163) 163
prednisone - administration & dosage (162) 162
antimitotic agents (158) 158
cisplatin - administration & dosage (158) 158
hodgkin disease - radiotherapy (157) 157
radiation (157) 157
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2488) 2488
German (39) 39
French (36) 36
Spanish (16) 16
Chinese (15) 15
Russian (14) 14
Japanese (13) 13
Polish (10) 10
Czech (3) 3
Hebrew (3) 3
Hungarian (3) 3
Italian (3) 3
Bulgarian (2) 2
Dutch (2) 2
Norwegian (2) 2
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 3, pp. 203 - 212
BEACOPP combination chemotherapy was compared with ABVD chemotherapy in advanced Hodgkin's disease. BEACOPP therapy was associated with higher initial rates of... 
CELL TRANSPLANT | MEDICINE, GENERAL & INTERNAL | VINORELBINE | MOPP | DISEASE | REGIMEN | IFOSFAMIDE | CHEMOTHERAPY | STANDARD | HYBRID | FERTILITY | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Young Adult | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Etoposide - adverse effects | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Combined Modality Therapy | Bleomycin - adverse effects | Remission Induction | Disease-Free Survival | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hodgkin Disease - therapy | Adolescent | Vincristine - therapeutic use | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Prednisone - therapeutic use | Procarbazine | Vinblastine | Disease | Etoposide | Prednisone | Family medical history | Radiation therapy | Patients | Lymphoma | Doxorubicin | Survival | Vincristine | Studies | Hepatitis | Dacarbazine | Cyclophosphamide | Chemotherapy | Bleomycin | Tomography | Lymphomas | Hodgkin's disease | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 5, pp. 592 - 598
Purpose To assess therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) risk in patients treated for Hodgkin lymphoma (HL) on successive... 
2ND CANCER-RISK | RANDOMIZED-TRIALS | ONCOLOGY | DNA TOPOISOMERASE-II | ALKYLATING-AGENTS | COMBINED-MODALITY TREATMENT | DISEASE | MYELOID-LEUKEMIA | MYELODYSPLASTIC SYNDROMES | CHEMOTHERAPY | ACUTE PROMYELOCYTIC LEUKEMIA | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Hodgkin Disease - pathology | Humans | Leukemia, Myeloid, Acute - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Mechlorethamine - adverse effects | Male | Risk | Leukemia, Myeloid, Acute - etiology | Incidence | Hodgkin Disease - radiotherapy | Melphalan - adverse effects | Chemotherapy, Adjuvant - adverse effects | Radiotherapy, Adjuvant - adverse effects | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Adult | Female | Retrospective Studies | Databases, Factual | Radiotherapy Dosage | Prednisone - adverse effects | Drug Administration Schedule | California - epidemiology | Clinical Trials as Topic | Bleomycin - adverse effects | Academic Medical Centers | Myelodysplastic Syndromes - epidemiology | Myelodysplastic Syndromes - etiology | Neoplasms, Second Primary - epidemiology | Neoplasms, Second Primary - etiology | Methotrexate - adverse effects | Procarbazine - adverse effects | Vincristine - adverse effects | Neoplasm Staging | Doxorubicin - adverse effects | Index Medicus | Hema14 | Hema13 | Hema12 | ORIGINAL REPORTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 684 - 691
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 2, pp. 231 - 239
Purpose To optimize fertility advice in patients with Hodgkin lymphoma (HL) before therapy and during survivorship, information on the impact of chemotherapy... 
INHIBIN-B | PRESERVATION | OUTCOME MEASURE | OVARIAN RESERVE | ONCOLOGY | TERM FOLLOW-UP | DISEASE | FEMALE CANCER SURVIVORS | ANTI-MULLERIAN HORMONE | CHEMOTHERAPY | SERUM MARKER | Procarbazine - administration & dosage | Cyclophosphamide - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vinblastine - administration & dosage | Cyclophosphamide - adverse effects | Gonadotropin-Releasing Hormone - analogs & derivatives | Fertility - physiology | Fertility Preservation | Young Adult | Vinblastine - adverse effects | Follicle Stimulating Hormone - blood | Hodgkin Disease - drug therapy | Oligospermia - epidemiology | Vincristine - administration & dosage | Adult | Female | Gonadotropin-Releasing Hormone - therapeutic use | Hodgkin Disease - physiopathology | Inhibins - blood | Menstrual Cycle - drug effects | Testosterone - blood | Menstrual Cycle - physiology | Doxorubicin - administration & dosage | Dacarbazine - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Prednisone - adverse effects | Survivors | Etoposide - administration & dosage | Ovary - physiology | Hodgkin Disease - epidemiology | Bleomycin - administration & dosage | Bleomycin - adverse effects | Germany - epidemiology | Randomized Controlled Trials as Topic | Pregnancy | Testis - physiology | Hodgkin Disease - blood | Procarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Index Medicus
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10028, pp. 1629 - 1637
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2009, Volume 27, Issue 35, pp. 5874 - 5880
Purpose The standard of care for anaplastic gliomas is surgery followed by radiotherapy. The NOA-04 phase III trial compared efficacy and safety of... 
MALIGNANT GLIOMA | SURVIVAL | ONCOLOGY | GLIOBLASTOMA-MULTIFORME | EUROPEAN ORGANIZATION | MGMT GENE | OLIGODENDROGLIAL TUMORS | RADIOTHERAPY | CHEMOTHERAPY | BRAIN-TUMORS | 1P/19Q LOSS | Procarbazine - administration & dosage | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lomustine - adverse effects | Middle Aged | Brain Neoplasms - pathology | DNA Repair Enzymes - genetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Glioma - radiotherapy | Glioma - genetics | Young Adult | DNA Methylation | Time Factors | Radiotherapy, Adjuvant - adverse effects | Glioma - pathology | Treatment Failure | Tumor Suppressor Proteins - genetics | Dacarbazine - analogs & derivatives | Vincristine - administration & dosage | Adult | Female | Brain Neoplasms - mortality | Chemotherapy, Adjuvant | Brain Neoplasms - radiotherapy | Promoter Regions, Genetic | Dacarbazine - administration & dosage | Glioma - mortality | Drug Administration Schedule | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Isocitrate Dehydrogenase - genetics | Brain Neoplasms - drug therapy | Disease Progression | Disease-Free Survival | DNA Modification Methylases - genetics | Procarbazine - adverse effects | Vincristine - adverse effects | Aged | Mutation | Antineoplastic Agents, Alkylating - adverse effects | Lomustine - administration & dosage | Glioma - drug therapy | Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 12/2017, Volume 318, Issue 23, pp. 2306 - 2316
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 5, pp. 399 - 408
In patients with limited-stage Hodgkin's disease, ABVD chemotherapy alone resulted in a higher rate of long-term (12-year) survival than either radiation... 
CLINICAL-PRACTICE GUIDELINES | MEDICINE, GENERAL & INTERNAL | INTERGROUP TRIAL | RANDOMIZED-TRIALS | DISEASE | DOXORUBICIN | VINBLASTINE | BLEOMYCIN | FIELD RADIOTHERAPY | CHEMOTHERAPY | COOPERATIVE-ONCOLOGY-GROUP | Doxorubicin - therapeutic use | Dacarbazine - adverse effects | Follow-Up Studies | Dacarbazine - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Neoplasms, Second Primary - mortality | Radiotherapy - adverse effects | Vinblastine - therapeutic use | Cause of Death | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Vinblastine - adverse effects | Hodgkin Disease - drug therapy | Hodgkin Disease - mortality | Adult | Female | Treatment Outcome | Combined Modality Therapy | Bleomycin - adverse effects | Hodgkin Disease - complications | Heart Diseases - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Neoplasm Staging | Doxorubicin - adverse effects | Drugs | Usage | Care and treatment | Vinblastine | Patient outcomes | Product/Service Evaluations | Radiotherapy | Doxorubicin | Dacarbazine | Bleomycin | Dosage and administration | Drug therapy, Combination | Drug therapy | Hodgkin's disease | Medical research | Clinical trials | Radiation therapy | Lymphoma | Survival | Patients | Chemotherapy | Lymphomas | Index Medicus | Abridged Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 06/2014, Volume 311, Issue 23, pp. 2397 - 2405
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 1, pp. 23 - 34
Journal Article